| Autor: |
Ambrosino E; Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonsaga, I-10043 Orbassano, Italy., Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer research [Cancer Res] 2006 Aug 01; Vol. 66 (15), pp. 7734-40. |
| DOI: |
10.1158/0008-5472.CAN-06-1432 |
| Abstrakt: |
To assess the role of CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cells in overcoming immunosurveillance of Erbb2 (HER-2/neu) mammary lesions, we studied the effects of their sustained removal in BALB/c female mice made transgenic for the rat Erbb2 (r-Erbb2) oncogene (BALB-neuT mice), which develop multiple mammary carcinomas. During the progression of these lesions, Treg cells expand in the spleen, tumor draining lymph nodes, and tumors. Repeated administration of anti-CD25 antibodies extends tumor-free survival, reduces carcinoma multiplicity, and leads to the manifestation of a natural antibody and CTL-mediated reactivity against r-Erbb2. Loss of Foxp3(+) Treg cells during anti-CD25 treatment remarkably caused the disappearance of Gr1(+) immature myeloid cells, suggesting a cross-talk between these two inhibitory immune cell types. Treg cell expansion associated with r-Erbb2 overexpression may be seen as a physiologic response to dampen the immune reaction elicited by local anomalous overexpression of a self-antigen. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
